AOD-9604 Peptide: What Is It Studied For?

What Is AOD-9604?

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH), spanning amino acids 177–191, with a tyrosine residue added at the N-terminus. That structural modification distinguishes it from the unmodified hGH fragment 176–191 — research on the unmodified fragment is not interchangeable with AOD-9604 findings. Early preclinical work focused on whether the compound could replicate hGH's fat-metabolism effects without triggering the diabetogenic side effects associated with full-length growth hormone. It carries a World Anti-Doping Agency (WADA) ban as a potential performance-enhancing agent, a classification documented in a 2015 analytical study published in Drug Testing and Analysis.

---

What Is AOD-9604 Studied For?

Research on AOD-9604 goes back to 2001 — nearly 30 years — with studies continuing through 2016.

1. Fat Metabolism and Weight Reduction — A 2001 preclinical study in obese ob/ob and lean C57BL/6J mice, published in the International Journal of Obesity, reported that chronic treatment increased fat oxidation rates and reduced body weight compared to untreated controls.

2. Lipolytic Mechanisms Independent of the hGH Receptor — A 2001 preclinical study in obese Zucker rats, published in Hormone Research, found that daily oral dosing over 19 days reduced body weight gain by more than 50% relative to controls, with in vitro assays indicating the compound's effects were not mediated through the hGH receptor.

3. Beta-Adrenergic Pathway Interaction — A 2001 mouse study published in Endocrinology examined how AOD-9604 affects lipid metabolism in beta(3)-adrenergic receptor knockout mice, reporting that the lipolytic response was attenuated in the absence of that receptor, implicating the beta-adrenergic pathway in the compound's mechanism.

4. Osteoarthritis and Joint Cartilage — A 2016 preclinical study using a collagenase-induced knee osteoarthritis model in 32 New Zealand white rabbits examined intra-articular injection of AOD-9604 with or without hyaluronic acid, assessing effects on cartilage and joint tissue.

5. Human Clinical Investigation — Three "Gateways to Clinical Trials" registry entries in Methods and Findings in Experimental and Clinical Pharmacology (2004–2005) document that AOD-9604 entered human clinical evaluation; however, as noted in the human research section below, these entries do not report compelling efficacy outcomes, and the available human data clusters around a small number of research groups.

---

How Does AOD-9604 Work?

The prevailing hypothesis from preclinical work is that AOD-9604 stimulates lipolysis — the breakdown of stored fat — through a pathway that does not require binding to the full hGH receptor. A 2001 study in Hormone Research used in vitro assays to confirm that the compound did not drive cell proliferation via the hGH receptor, distinguishing its activity profile from full-length growth hormone. The 2001 Endocrinology study added specificity to this picture by testing the compound in beta(3)-adrenergic receptor knockout mice: when that receptor was absent, the lipolytic effect diminished, pointing to beta(3)-AR signaling as a contributing pathway.

A 2015 Drug Testing and Analysis study examined the compound's in vitro metabolic profile in human samples, identifying metabolites relevant to anti-doping detection. That work confirmed the peptide's structural identity — amino acids 177–191 plus the N-terminal tyrosine — and described its metabolic breakdown products, though it was not designed to assess therapeutic efficacy.

---

What Does Animal Research Show?

Three preclinical rodent studies, all published in 2001, form the primary evidence base for AOD-9604's metabolic effects.

The International Journal of Obesity study administered hGH or AOD-9604 chronically to obese ob/ob mice and lean controls. Both compounds reduced body weight and increased fat oxidation in the obese animals; AOD-9604 produced these effects without the insulin-resistance signals associated with full-length hGH. The lean mice showed little change, suggesting the effect was tied to an already-elevated adiposity state.

The Hormone Research study focused on obese Zucker rats given oral AOD-9604 for 19 days. Body weight gain dropped by more than 50% relative to controls. Adipose tissue analysis from treated animals showed changes consistent with increased lipolytic activity. The in vitro component of that same study found no evidence that the compound triggered proliferation through the hGH receptor — a finding that researchers interpreted as a potential safety advantage over full-length hGH.

The Endocrinology study used beta(3)-adrenergic receptor knockout mice to probe mechanism. In normal mice, both hGH and AOD-9604 produced lipolytic effects after chronic treatment. In the knockouts, the AOD-9604 response was blunted, supporting the beta(3)-AR pathway as functionally relevant. That study did not establish whether this pathway interaction is the sole mechanism or one of several.

The 2016 rabbit osteoarthritis study in the Annals of Clinical and Laboratory Science took the compound in a different direction entirely. Thirty-two mature New Zealand white rabbits received collagenase-induced knee osteoarthritis and were then assigned to saline, hyaluronic acid, AOD-9604, or a combination of the latter two via weekly intra-articular injection. The study assessed joint tissue outcomes histologically. This line of research — cartilage and connective tissue — is distinct from the metabolic work and remains limited to the single animal model.

---

What Does Human Research Show?

Human investigation of AOD-9604 is documented primarily through three entries in the "Gateways to Clinical Trials" series, a registry-style summary published in Methods and Findings in Experimental and Clinical Pharmacology in 2004 and 2005. These entries — authored by Bayés, Rabasseda, and Prous, who account for three of the eight primary studies in the available literature — catalogued the compound's entry into clinical evaluation rather than reporting detailed outcome data. Three of the eight primary studies in the pool originate from this single journal; the human clinical evidence base is therefore narrow and concentrated around a limited number of research groups.

The registry entries indicate that clinical trials were initiated, with obesity as the primary indication. They do not present efficacy data in the form of controlled trial results, effect sizes, or responder rates. No phase III randomized controlled trial results appear in the available study pool. The 2015 Drug Testing and Analysis work, while conducted using human biological samples, was an analytical study focused on detection and metabolism — not a clinical efficacy trial.

The honest summary: human evidence for AOD-9604 is sparse, the available documentation does not demonstrate compelling clinical efficacy, and the outcomes reported in registry form were not impressive enough to generate the volume of follow-on trial literature seen with compounds that advance through late-stage development. That absence is itself informative.

---

What Is Still Unknown About AOD-9604?

Several gaps limit what can be concluded from the current literature.

The rodent weight-loss findings, while consistent across the 2001 studies, were generated in obese mouse and rat models with high adiposity at baseline. Whether those mechanisms translate to human adipose tissue regulation remains unresolved by the available trial data.

The osteoarthritis research is confined to a single 32-rabbit preclinical model. No human joint or cartilage trial data appears in the pool, and the mechanism by which a lipolytic peptide might affect cartilage is not established in the available studies.

The WADA ban classification, described in the 2015 Drug Testing and Analysis study, reflects regulatory concern about potential performance-enhancement use — but the performance-relevant mechanism is not characterized in any of the primary studies available here.

Finally, the in vitro metabolite data from the 2015 analytical study covers detection, not pharmacokinetics or bioavailability in a therapeutic context. Long-term safety, optimal formulation, and clinical dose-response data are not addressed in the available literature.

---

Where Can I Buy AOD-9604?

AOD-9604 is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---